Effects of rosuvastatin and/or β-carotene on non-alcoholic fatty liver in rats

Research in Pharmaceutical Sciences

Volumn 10, Issue 4, 2015, Pages 275-287

  El Din, Sayed H Seif ^a   El Lakkany, Naglaa M ^a   El Naggar, Abeer A ^a   Hammam, Olfat A ^b   El Latif, Hekma A Abd ^c   Ain Shoka, Afaf A ^d   Ebeid, Fatma A ^a  

^a Giza   (Egypt)

^b Theodor Bilharz Research Institute   (Egypt)

^c UMM AL QURA UNIVERSITY   (Saudi Arabia)

^d CAIRO UNIVERSITY   (Egypt)

Author keywords

NAFLD; Oxidative stress; Rosuvastatin; TNF TGF 1; carotene

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BETA CAROTENE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; ROSUVASTATIN; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FATTY LIVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; INFLAMMATION; LIPID DIET; LIPID PEROXIDATION; LIVER LEVEL; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84941567403     PISSN: 17355362     EISSN: 17359414     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi KN, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, American College of Gastroenterology and the American Gastroenterological Association.Am J Gastroenterol. 2012;142:1592-1609.
2. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28:155-161.
3. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-131.
4. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric non-alcoholic fatty liver disease. Hepatology. 2009;50:1282-1293.
5. Anania FA. Non-alcoholic fatty liver disease and fructose: bad for us, better for mice. J Hepatol. 2011;55:218-220.
6. Bjornsson E, Angulo P. Non-alcoholic fatty liver disease. Scand J Gastroenterol. 2007;42:1023-1030.
7. Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 2008;57:1711-1718.
8. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004;140:650-658.
9. Fraulob JC, Souza-Mello V, Aguila MB, Mandarim-de-Lacerda CA. Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. Clin Sci (Lond). 2012;123:259-270.
10. Puccetti L, Pasqui AL, Scarpini F, Cappellone R, Ghezzi A, Ceccatelli L, et al. Statins discontinuation in compliant chronic users induces atherothrombotic profile despite baseline clinical setting and treatments. Int J Cardiol. 2011;3:328-329.
11. Parson HK, Bundy MA, Dublin CB, Boyd AL, Paulson JF, Vinik AI. Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes. Diabetes Metab Syndr Obes. 2010;3:19-26.
12. Day CP. From fat to inflammation. Gastroenterology. 2006;130:207-210.
13. Kolak M, Westerbacka J, Velagapudi VR Wågsäter D, Yetukuri L, Makkonen J, et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes. 2007;56:1960-1968.
14. Burri BJ. Lycopene and human health. In: Meskin MS, Bidlack WR, Davies AJ, Omaye ST, editors. Phytonutrients in health and disease. Boca Raton: CRC Press; 2002. p. 157-172.
15. Institute of Medicine (IOM). Vitamin A. In: Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Washington: National Academy Press; 2001. p. 82-161.
16. Delport R Ubbink JB, Human JA, Becker PJ, Myburgh DP, Vermaak WJ. Antioxidant vitamins and coronary artery disease risk in South African males. Clin Chim Acta. 1998;278:55-60.
17. Sarni RO, Ramalho RA. Serum retinol and total carotene concentrations in obese children. Med Sci Monit. 2005;11:510-514.
18. Duvnjak M, Tomasic V, Gomercic M, Smircic-Duvnjak L, Barsic N, Lerotic I. Therapy of nonalcoholic fatty liver disease: current status. J Physiol Pharmacol. 2009;60:57-66.
19. Zulet MA, Barber A, Garcin H, Higueret P, Martinez JA. Alterations in carbohydrate and lipid metabolism induced by a diet rich in coconut oil and cholesterol in a rat model. J Am Coll Nutr. 1999;1:36-42.
20. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82:70-77.
21. Winterbourn CC, Hawkins RE, Brian M, Carrell RW. The estimation of red cell superoxide dismutase activity. J Lab Clin Med. 1975;85:337-342.
22. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-358.
23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic steatohepatitis clinical research network. design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
24. Xiao J, Fai SK, Liong EC, Tipoe GL. Recent advances in the herbal treatment of non-alcoholic fatty liver disease. J Tradit Complement Med. 2013;3:88-94.
25. Kaser S, Ebenbichler CF, Tilg H. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. Int J Clin Pract. 2010;64:968-983.
26. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:81-128.
27. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114:842-845.
28. Valero-Muñoz M, Martín-Fernández B, Ballesteros S, Cachofeiro V, Lahera V, de Las Heras N. Rosuvastatin improves insulin sensitivity in overweight rats induced by high fat diet. Role of SIRT1 in adipose tissue. Clin Investig Arterioscler. 2014;26:161-167.
29. Chung HK, Kang B, Lee JH, Shim JY, Park S, Lee SH et al. Increased arterial stiffness is associated with reduced plasma levels of beta-carotene in treated hypertensive patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2009;6:e9-e11
30. van Helden YG, Godschalk RW, Swarts HJ, Hollman PC, van Schooten FJ, Keijer J. Beta-carotene affects gene expression in lungs of male and female Bcmo1 (-/-) mice in opposite directions. Cell Mol Life Sci. 2011;68:489-504.
31. AL-Dosari M, ALqasoumi S, Ahmad M, AL-yahya M, Ansari MN, Rafatullah S. Effect of Beta vulgaris L. on cholesterol rich diet-induced hypercholesterolemia in rats. Farmacia. 2011;59:669-678.
32. Naik SR, Panda VS. Antioxidant and hepatoprotective effects of Ginkgo biloba phytosomes in carbon tetrachloride-induced liver injury in rodents. Liver Int. 2007;27:393-399.
33. El-Attar M, El-Melegy N. Serum levels of leptin and adiponectin in patients with nonalcoholic fatty liver disease: potential biomarkers. JASMR. 2010;5:101-108.
34. Olorunnisola OS, Bradley G, Afolayan AJ. Protective effect of Tulbaghia violacea Harv. on aortic pathology, tissue antioxidant enzymes and liver damage in diet-induced atherosclerotic rats. Int J Mol Sci. 2012;13:12747-12760.
35. Neto-Ferreira R, Rocha VN, Souza-Mello V, Mandarim-de-Lacerda CA, de-Carvalho JJ. Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice. Diabetol Metab Syndr. 2013;5:32.
36. Rizos CV, Milionis HJ, Kostapanos MS, Florentin M, Kostara CE, Elisaf MS, et al. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipemia: a 24-week, randomized, open-label, prospective study. Clin Ther. 2010;32:492-505.
37. Calamita G, Portincasa P. Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin Ther Targets. 2007;11:1231-1249.
38. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93:S57-S63.
39. Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis. 2006;184:233-234.
40. Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J Obes. 2012; 2012:ID 483135.
41. Awad AS, Kamel R. Effect of Rosuvastatin on cholestasis-induced hepatic injury in rat livers. J Biochem mol Toxicol. 2010;24:89-94.
42. Ansari JA, Bhandari U, Pillai KK, Haque SE. Effect of rosuvastatin on obesity-induced cardiac oxidative stress in Wistar rats-a preliminary study. Indian J Exp Biol. 2012;50:216-222.
43. Kostapanos MS, Milioni HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, et al. A 12-weeks, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther. 2007;7:1403-1414.
44. Malaguarnera M, Vacante M, Russo C, Gargante MP, Giordano M, Bertino G, et al. Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with a-interferon and ribavirin. Hepat Mon. 2011;2:92-98.
45. Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J Gastroenterol. 2008;43:811-822.
46. De las Heras N, Valero-Munoz M, Ballesteros S, Gomez-Hernandez A, Martn-Fernandez B, Blanco-Rivero J, et al. Factors involved in rosuvastatin induction of insulin sensitization in rats fed a high fat diet. Nutr Metab Cardiovasc Dis. 2013;23:1107-1114.
47. Hasegawa T, Yoneda M, Nakamura K. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther. 2001;15:1667-1672.
48. Yang Z, Wang X, We J, Ye Z, Li Q, He M, et al. Prevalence of non-alcoholic fatty liver disease and its relation to hypoadiponectinaemia in the middle-aged andelderly Chinese population. Arch Med Sci. 2011;7:665-672.
49. Ma YX, Li WH, Xie Q. Rosuvastatin inhibits TGF-beta1 expression and alleviates myocardial fibrosis in diabetic rats. Pharmazie. 2013;5:355-358.
50. Vardi N, Parlakpinar H, Cetin A, Erdogan A, Cetin Ozturk I. Protective effect of beta-carotene on methotrexate-induced oxidative liver damage. Toxicol Pathol. 2010;38:592-597.
51. Nierenberg DW, Bayrd GT, Stukel TA. Lack of effect of chronic administration of oral b-carotene on serum cholesterol and triglyceride concentrations. Am J Clin Nut 1991;53:652-654.
52. Erdman JW Jr, Breirer TL, Guggr ET. Absorption and transport of carotenoids. Ann N Y Acad Sci. 1993;691:76-85.
53. Erhardt A, Stahl W, Sies H, lirussi F, Donner A, Häussinger D. Plasma levels of vitamin E and carotenoids are decreased in patient with non alcoholic steatohepatitis (NASH). Eur J Med Res. 2011;16:76-78.
54. Rydén M, Leanderson P, Kastbom KO, Jonasson L. Effects of simvastatin on carotenoid status in plasma. Nutr Metab Cardiovasc Dis. 2012;1:66-71.
55. Canas JA, Damaso L, Altomare A, Killen K, Hossain J, Balagopal P. Insulin resistance and adiposity in relation to serum p-carotene levels. J Pediatr. 2012;161:58-64.
56. Kameji H, Mochizuki K, Miyoshi N, Goda T. Beta-carotene accumulation in 3T3-L1 adipocytes inhibits the elevation of reactive oxygen species and the suppression of genes related to insulin sensitivity induced by tumor necrosis factor-alpha. Nutrition. 2010;26:1151-1156.
57. Garcia-Ruiz C, Colell A, Morales A, Kaplowitz N, Fernandez Checa JC. Role of oxidative stress generated form the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes. Mol Pharmacol. 1995;48:825-834.
58. Thong-Ngam D, Samuhasaneeto S, Kulaputana O, Klaikeaw N. N-acetylcysteine attenuates oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis. World J Gastroenterol. 2007;13:5127-5132.
59. Khan MA, Rahman MM, Tania M, Uddin MN, Ahmed S. Pleurotus sajor-caju and Pleurotus florida mushrooms improve some extent of the antioxidant systems in the liver of hypercholesterolemic rats. Open Nutraceuticals J. 2011;4:20-24.
60. Chenni A, Yahia DA, Boukortt FO, Prost J, Lacaille-Dubois MA, Bouchenak M. Effect of aqueous extract of Ajuga iva supplementation on plasma lipid profile and tissue antioxidant status in rats fed a high-cholesterol diet. J Ethnopharmacol. 2007;109:207-213.
61. El-Demerdash FM, Yousef MI, Kedwany FS, Baghdadi HH. Cadmium-induced changes in lipid peroxidation, blood hematology, biochemical parameters and semen quality of male rats: protective role of vitamin E and P-carotene. Food
62. Shih T, Vourvahis M, Singh M, Papay J. Pharmacogenetics: from bench science to the bedside. Ther Innov Regul Sci. 2008;42:503-513.
63. Berryman AM, Maritim AC, Sanders RA, Watkins JB. Influence of treatment of diabetic rats with combinations of pycnogenol, P-carotene, and alfa-lipoic acid on parameters of oxidative stress. J Biochem Mol Toxicol. 2004;18:345-352.
64. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005;100:1072-1081.
65. Mecocci P, Polidori MC, Troiano L, Cherubini A, Cecchetti R, Pini G, et al. Plasma antioxidants and longevity: a study on healthy centenarians. Free Radic Biol Med. 2000;28:1243-1248.